Skip to content

INKT - MiNK Therapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchI

Mink Therapeutics Inc

INKT · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

I

INKTMink Therapeutics Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $16.98
52-wk low: $8.48
Prev close: $13.57
Mkt cap: $56.8M
Beta: 0.48
P/B: 11.3x

Smart money

5 funds hold a position and insiders have been net selling.

Real smart money

Funds holding this stock

5 holders

Combined position$459K

CI
Citadel
Ken Griffin · Q2 2026 13F
$180K
position
JS
Jim Simons
Q4 2025 13F

Earnings

Reported Aug 13, 2026

Earnings came in 3.3% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $57M

Valuation

P/B11.33

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: INKT
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $56.80M
Beta: 0.48

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

Profit margin

+0.0%

Op margin

+0.0%

ROE

-1239.0%

$116K

position

BR

BlackRock

Q2 2026 13F

$156K

position

2 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 2 holders

Coverage gaps for INKT

No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.62-3.3%

-$0.60 expected

Next report

What the street expects next

EPS expected

-$0.35

-$0.35 to -$0.35

Revenue expected

$1.6M

1 analysts

Last 30 days

1up0down

Analysts raising estimates

Estimate drift

+0.28

Change in 30 days

-1239.0%

ROA-129.3%

Growth

Beta0.48